Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
09 2019
Historique:
received: 05 04 2019
revised: 24 07 2019
accepted: 30 07 2019
pubmed: 20 8 2019
medline: 5 8 2020
entrez: 19 8 2019
Statut: ppublish

Résumé

To determine the frequency of mutations known to cause autosomal dominant Parkinson disease (PD) in a series with more than 10% of Sweden's estimated number of PD patients. The Swedish Parkinson Disease Genetics Network was formed as a national multicenter consortium of clinical researchers who together have access to DNA from a total of 2,206 PD patients; 85.4% were from population-based studies. Samples were analyzed centrally for known pathogenic mutations in SNCA (duplications/triplications, p.Ala30Pro, p.Ala53Thr) and LRRK2 (p.Asn1437His, p.Arg1441His, p.Tyr1699Cys, p.Gly2019Ser, p.Ile2020Thr). We compared the frequency of these mutations in Swedish patients with published PD series and the gnomAD database. A family history of PD in first- and/or second-degree relatives was reported by 21.6% of participants. Twelve patients (0.54%) carried LRRK2 p.(Gly2019Ser) mutations, one patient (0.045%) an SNCA duplication. The frequency of LRRK2 p.(Gly2019Ser) carriers was 0.11% in a matched Swedish control cohort and a similar 0.098% in total gnomAD, but there was a marked difference between ethnicities in gnomAD, with 42-fold higher frequency among Ashkenazi Jews than all others combined. In relative terms, the LRRK2 p.(Gly2019Ser) variant is the most frequent mutation among Swedish or international PD patients, and in gnomAD. SNCA duplications were the second most common of the mutations examined. In absolute terms, however, these known pathogenic variants in dominant PD genes are generally very rare and can only explain a minute fraction of familial aggregation of PD. Additional genetic and environmental mechanisms may explain the frequent co-occurrence of PD in close relatives.

Identifiants

pubmed: 31422003
pii: S1353-8020(19)30352-9
doi: 10.1016/j.parkreldis.2019.07.032
pii:
doi:

Substances chimiques

SNCA protein, human 0
alpha-Synuclein 0
LRRK2 protein, human EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-165

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Andreas Puschmann (A)

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden. Electronic address: Andreas.Puschmann@med.lu.se.

Itzia Jiménez-Ferrer (I)

Lund University, Department of Experimental Medical Science, Lund, Sweden.

Elin Lundblad-Andersson (E)

Department of Clinical Genetics and Pathology, Division of Laboratory Medicine, Office for Medical Services, Region Skåne, Sweden.

Emma Mårtensson (E)

Department of Clinical Genetics and Pathology, Division of Laboratory Medicine, Office for Medical Services, Region Skåne, Sweden.

Oskar Hansson (O)

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden.

Per Odin (P)

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.

Håkan Widner (H)

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.

Kajsa Brolin (K)

Lund University, Department of Experimental Medical Science, Lund, Sweden.

Ropafadzo Mzezewa (R)

Lund University, Department of Experimental Medical Science, Lund, Sweden.

Jonas Kristensen (J)

Department of Clinical Genetics and Pathology, Division of Laboratory Medicine, Office for Medical Services, Region Skåne, Sweden.

Maria Soller (M)

Department of Clinical Genetics and Pathology, Division of Laboratory Medicine, Office for Medical Services, Region Skåne, Sweden.

Emil Ygland Rödström (EY)

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.

Owen A Ross (OA)

Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.

Mathias Toft (M)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Guido J Breedveld (GJ)

Erasmus MC, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, The Netherlands.

Vincenzo Bonifati (V)

Erasmus MC, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, The Netherlands.

Lovisa Brodin (L)

Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden.

Anna Zettergren (A)

Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Olof Sydow (O)

Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden.

Jan Linder (J)

Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.

Karin Wirdefeldt (K)

Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Per Svenningsson (P)

Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden.

Hans Nissbrandt (H)

Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Andrea Carmine Belin (AC)

Department of Neuroscience, Karolinska Institutet, Solna, Sweden.

Lars Forsgren (L)

Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.

Maria Swanberg (M)

Lund University, Department of Experimental Medical Science, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH